Mouse models of Mdm2 and Mdm4 and their clinical implications

Shunbin Xiong1

  • 1Department of Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. sxiong@mdanderson.org

Chinese Journal of Cancer
|January 19, 2013
PubMed

Insights

Mdm2 and Mdm4 proteins regulate the tumor suppressor p53. Inhibiting their interaction is crucial for embryogenesis and blocking p53. This suggests targeting Mdm2/Mdm4 is a promising cancer therapy strategy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Mdm2 and Mdm4 are critical negative regulators of the tumor suppressor p53.
  • Their functions are essential for embryonic development, as evidenced by embryonic lethality in knockout models.

Purpose of the Study:

  • To investigate the roles of Mdm2 and Mdm4 in p53 regulation and embryonic development.
  • To explore the therapeutic potential of targeting the Mdm2-Mdm4 interaction in cancer.

Main Methods:

  • Utilized knockout and knockin mouse models to study Mdm2 and Mdm4 function.
  • Analyzed p53-dependent apoptosis and cell cycle arrest phenotypes.
  • Assessed the impact of Mdm2/Mdm4 disruption on embryonic lethality and tumorigenesis.

Main Results:

  • Deletion of Mdm2 or Mdm4 leads to p53-dependent embryonic lethality.
  • Mdm2 deletion causes more severe defects than Mdm4 deletion.
  • Disrupting the Mdm2-Mdm4 interaction is lethal but rescued by p53 loss, highlighting its importance in inhibiting p53 during embryogenesis.
  • Overexpression of Mdm2/Mdm4 induces tumors, confirming their oncogenic potential.

Conclusions:

  • Mdm2 and Mdm4 are essential oncogenes that inhibit p53.
  • Their heterodimerization is critical for suppressing p53 activity during embryogenesis.
  • Targeting Mdm2/Mdm4-mediated p53 inhibition represents a potential therapeutic strategy for cancers with wild-type p53.